Effect of low dose acetylsalicylic acid and anticoagulant on clinical outcomes in COVID-19, analytical cross-sectional study.
ASA
COVID‐19
acetylsalicylic acid
anticoagulation
preventative medicine
Journal
Health science reports
ISSN: 2398-8835
Titre abrégé: Health Sci Rep
Pays: United States
ID NLM: 101728855
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
30
10
2021
revised:
13
05
2022
accepted:
26
05
2022
entrez:
18
7
2022
pubmed:
19
7
2022
medline:
19
7
2022
Statut:
epublish
Résumé
The therapeutic strategy for the treatment of known sequelae of COVID-19 has shifted from reactive to preventative. In this study, we aim to evaluate the effects of acetylsalicylic acid (ASA), and anticoagulants on COVID-19 related morbidity and mortality. This record-based analytical cross-sectional study targeted 539 COVID-19 patients in a single United States medical center between March and December 2020. Through a random stratified sample, we recruited outpatient ( Age, mean number of comorbidities, and all individual comorbidities except for asthma, and malignancy were significantly lower in the SC compared to ASA and AC. After adjusting for age and comorbidity via binary logistic regression models, no statistical differences were found between groups for the studied outcomes. When compared to the SC group, ASA had lower 30-day readmission rates (odds ration [OR] 0.81 95% confidence interval [CI] 0.35-1.88, Low-dose ASA has a nonsignificant but potentially protective role in reducing the risk of COVID-19 related morbidity and mortality. Our data suggests a trend toward reduced 30-day readmission rates, ARDS, MICU admissions, need for mechanical ventilation, and mortality compared to the standard management protocol. Further randomized control trials are needed to establish causal effects.
Sections du résumé
Background and aims
UNASSIGNED
The therapeutic strategy for the treatment of known sequelae of COVID-19 has shifted from reactive to preventative. In this study, we aim to evaluate the effects of acetylsalicylic acid (ASA), and anticoagulants on COVID-19 related morbidity and mortality.
Methods
UNASSIGNED
This record-based analytical cross-sectional study targeted 539 COVID-19 patients in a single United States medical center between March and December 2020. Through a random stratified sample, we recruited outpatient (
Results
UNASSIGNED
Age, mean number of comorbidities, and all individual comorbidities except for asthma, and malignancy were significantly lower in the SC compared to ASA and AC. After adjusting for age and comorbidity via binary logistic regression models, no statistical differences were found between groups for the studied outcomes. When compared to the SC group, ASA had lower 30-day readmission rates (odds ration [OR] 0.81 95% confidence interval [CI] 0.35-1.88,
Conclusion
UNASSIGNED
Low-dose ASA has a nonsignificant but potentially protective role in reducing the risk of COVID-19 related morbidity and mortality. Our data suggests a trend toward reduced 30-day readmission rates, ARDS, MICU admissions, need for mechanical ventilation, and mortality compared to the standard management protocol. Further randomized control trials are needed to establish causal effects.
Identifiants
pubmed: 35844823
doi: 10.1002/hsr2.699
pii: HSR2699
pmc: PMC9273938
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e699Informations de copyright
© 2022 The Authors. Health Science Reports published by Wiley Periodicals LLC.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Circulation. 2020 Jun 2;141(22):1736-1738
pubmed: 32298134
J Med Virol. 2021 Sep;93(9):5390-5395
pubmed: 33913549
J Infect Dis. 2017 Feb 15;215(4):503-509
pubmed: 28158479
Health Sci Rep. 2021 Dec 23;4(4):e442
pubmed: 34988293
Influenza Other Respir Viruses. 2017 Jan;11(1):85-92
pubmed: 27542891
Anesth Analg. 2021 Apr 1;132(4):930-941
pubmed: 33093359
Medicine (Baltimore). 2021 Feb 12;100(6):e24544
pubmed: 33578548
JAMA. 2021 Apr 27;325(16):1620-1630
pubmed: 33734299
Fam Med Community Health. 2021 Apr;9(2):
pubmed: 33879541
Int J Infect Dis. 2021 Jul;108:6-12
pubmed: 34000418
PLoS One. 2016 May 16;11(5):e0154754
pubmed: 27182704
Br J Haematol. 2020 Jul;190(1):e11-e13
pubmed: 32374029
Am J Cardiol. 2021 Mar 1;142:158-159
pubmed: 33417877
J Cell Mol Med. 2021 Jan;25(2):1263-1273
pubmed: 33336936
Intern Emerg Med. 2022 Apr;17(3):761-775
pubmed: 34843073
FEBS J. 2021 Sep;288(17):5179-5189
pubmed: 33621437
J Stroke Cerebrovasc Dis. 2020 Aug;29(8):104949
pubmed: 32410807